25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

8AP (AGIOS PHARM (8AP.SG)) Stock Analysis
Buy, Hold or Sell?

Let's analyze AGIOS PHARM (8AP.SG) together

I guess you are interested in AGIOS PHARM (8AP.SG). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – AGIOS PHARM (8AP.SG)’s Financial Insights
  • 📈 Technical Analysis (TA) – AGIOS PHARM (8AP.SG)’s Price Targets

I'm going to help you getting a better view of AGIOS PHARM (8AP.SG). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AGIOS PHARM (8AP.SG)

I send you an email if I find something interesting about AGIOS PHARM (8AP.SG).

1. Quick Overview

1.1. Quick analysis of AGIOS PHARM (8AP.SG) (30 sec.)










1.2. What can you expect buying and holding a share of AGIOS PHARM (8AP.SG)? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€24.84
Expected worth in 1 year
€36.32
How sure are you?
19.0%

+ What do you gain per year?

Total Gains per Share
€11.48
Return On Investment
40.1%

For what price can you sell your share?

Current Price per Share
€28.60
Expected price per share
€25.40 - €30.80
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of AGIOS PHARM (8AP.SG) (5 min.)




Live pricePrice per Share (EOD)
€28.60
Intrinsic Value Per Share
€-72.87 - €-85.34
Total Value Per Share
€-48.04 - €-60.51

2.2. Growth of AGIOS PHARM (8AP.SG) (5 min.)




Is AGIOS PHARM (8AP.SG) growing?

Current yearPrevious yearGrowGrow %
How rich?$1.5b$924.6m$218.3m19.1%

How much money is AGIOS PHARM (8AP.SG) making?

Current yearPrevious yearGrowGrow %
Making money$168.4m-$88m$256.4m152.3%
Net Profit Margin1,890.9%-1,319.5%--

How much money comes from the company's main activities?

2.3. Financial Health of AGIOS PHARM (8AP.SG) (5 min.)




2.4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of AGIOS PHARM (8AP.SG)?

Welcome investor! AGIOS PHARM (8AP.SG)'s management wants to use your money to grow the business. In return you get a share of AGIOS PHARM (8AP.SG).

First you should know what it really means to hold a share of AGIOS PHARM (8AP.SG). And how you can make/lose money.

Speculation

The Price per Share of AGIOS PHARM (8AP.SG) is €28.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AGIOS PHARM (8AP.SG).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AGIOS PHARM (8AP.SG), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €24.84. Based on the TTM, the Book Value Change Per Share is €2.87 per quarter. Based on the YOY, the Book Value Change Per Share is €-1.27 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AGIOS PHARM (8AP.SG).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-1.69-5.9%2.9510.3%-1.58-5.5%0.933.2%0.712.5%
Usd Book Value Change Per Share-1.57-5.5%3.1210.9%-1.38-4.8%0.883.1%1.284.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.57-5.5%3.1210.9%-1.38-4.8%0.883.1%1.284.5%
Usd Price Per Share34.30-37.61-24.32-34.44-30.64-
Price to Earnings Ratio-5.08--4.00--3.88--4.54--4.11-
Price-to-Total Gains Ratio-21.89--17.45--17.67--22.25--20.95-
Price to Book Ratio1.27-2.20-1.48-2.39-2.20-
Price-to-Total Gains Ratio-21.89--17.45--17.67--22.25--20.95-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share31.0453
Number of shares32
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.120.88
Usd Total Gains Per Share3.120.88
Gains per Quarter (32 shares)99.7128.15
Gains per Year (32 shares)398.82112.61
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103993890113103
207987880225216
30119611870338329
40159515860450442
50199419850563555
60239323840676668
70279227830788781
80319131820901894
9035893581010131007
10039883980011261120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%3.018.00.014.3%3.018.00.014.3%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%4.017.00.019.0%4.017.00.019.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%4.017.00.019.0%4.017.00.019.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AGIOS PHARM (8AP.SG) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.4432.870-150%-1.267-12%0.810-278%1.183-222%
Book Value Per Share--24.83618.472+34%15.276+63%16.997+46%14.523+71%
Current Ratio--11.89810.955+9%13.902-14%14.867-20%13.420-11%
Debt To Asset Ratio--0.0730.109-33%0.116-37%0.166-56%0.189-61%
Debt To Equity Ratio--0.0790.123-36%0.132-40%0.247-68%0.278-71%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1693528354.4001857101241.250-9%1138330110.800+49%1738216233.514-3%1784103991.715-5%
Eps---1.5562.719-157%-1.454-7%0.856-282%0.656-337%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--42.83355.810-23%46.451-8%infnan%infnan%
Free Cash Flow Per Share---2.162-1.583-27%-1.299-40%-1.362-37%-1.362-37%
Free Cash Flow To Equity Per Share---2.084-1.524-27%-1.277-39%-1.778-15%-1.778-15%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---85.343--------
Intrinsic Value_10Y_min---72.874--------
Intrinsic Value_1Y_max---6.037--------
Intrinsic Value_1Y_min---5.929--------
Intrinsic Value_3Y_max---20.056--------
Intrinsic Value_3Y_min---19.108--------
Intrinsic Value_5Y_max---36.385--------
Intrinsic Value_5Y_min---33.607--------
Market Cap--1806138606.0001973565102.750-8%1249381461.700+45%1905110820.534-5%1709773824.251+6%
Net Profit Margin---8.99618.909-148%-13.195+47%-6.512-28%-6.020-33%
Operating Margin----0%-0%-0.3650%-0.9070%
Operating Ratio--12.77012.7760%15.786-19%15.932-20%14.059-9%
Pb Ratio1.152-10%1.2722.198-42%1.476-14%2.394-47%2.202-42%
Pe Ratio-4.596+9%-5.078-4.003-21%-3.875-24%-4.541-11%-4.108-19%
Price Per Share28.600-10%31.60034.650-9%22.400+41%31.7260%28.225+12%
Price To Free Cash Flow Ratio-3.307+9%-3.654-5.909+62%-4.415+21%-6.239+71%-5.199+42%
Price To Total Gains Ratio-19.814+9%-21.892-17.446-20%-17.674-19%-22.250+2%-20.954-4%
Quick Ratio--10.1238.396+21%11.385-11%10.311-2%9.410+8%
Return On Assets---0.0580.063-193%-0.085+47%-0.003-95%-0.024-59%
Return On Equity---0.0630.066-195%-0.097+54%-0.019-70%-0.047-25%
Total Gains Per Share---1.4432.870-150%-1.267-12%0.810-278%1.183-222%
Usd Book Value--1540898368.2461142972251.239+35%924621417.866+67%1076064253.692+43%990123093.011+56%
Usd Book Value Change Per Share---1.5673.116-150%-1.376-12%0.880-278%1.284-222%
Usd Book Value Per Share--26.95920.052+34%16.582+63%18.450+46%15.765+71%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1838325028.7012015883397.377-9%1235657335.273+49%1886833721.479-3%1936644883.007-5%
Usd Eps---1.6892.952-157%-1.578-7%0.929-282%0.712-337%
Usd Free Cash Flow---134128983.388-97877839.232-27%-78637308.855-41%-86955497.743-35%-72462914.786-46%
Usd Free Cash Flow Per Share---2.347-1.718-27%-1.410-40%-1.478-37%-1.478-37%
Usd Free Cash Flow To Equity Per Share---2.262-1.655-27%-1.386-39%-1.930-15%-1.930-15%
Usd Market Cap--1960563456.8132142304919.035-8%1356203576.675+45%2067997795.689-5%1855959486.224+6%
Usd Price Per Share31.045-10%34.30237.613-9%24.315+41%34.4390%30.638+12%
Usd Profit---96519390.040168424950.671-157%-88018707.977-9%68356493.372-241%39819719.020-342%
Usd Revenue--10729598.6989124158.744+18%6705499.205+60%14037324.984-24%16610587.074-35%
Usd Total Gains Per Share---1.5673.116-150%-1.376-12%0.880-278%1.284-222%
 EOD+3 -3MRQTTM+12 -23YOY+17 -185Y+10 -2410Y+12 -22

3.3 Fundamental Score

Let's check the fundamental score of AGIOS PHARM (8AP.SG) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.596
Price to Book Ratio (EOD)Between0-11.152
Net Profit Margin (MRQ)Greater than0-8.996
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.123
Current Ratio (MRQ)Greater than111.898
Debt to Asset Ratio (MRQ)Less than10.073
Debt to Equity Ratio (MRQ)Less than10.079
Return on Equity (MRQ)Greater than0.15-0.063
Return on Assets (MRQ)Greater than0.05-0.058
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of AGIOS PHARM (8AP.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.985
Ma 20Greater thanMa 5031.400
Ma 50Greater thanMa 10031.924
Ma 100Greater thanMa 20038.774
OpenGreater thanClose28.600
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About AGIOS PHARM (8AP.SG)

  • Other
  • 0

There is no Profile data available for 8AP.SG.

Fundamental data was last updated by Penke on 2025-03-11 18:34:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit AGIOS PHARM (8AP.SG) earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • A Net Profit Margin of -899.6% means that €-9.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AGIOS PHARM (8AP.SG):

  • The MRQ is -899.6%. The company is making a huge loss. -2
  • The TTM is 1,890.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-899.6%TTM1,890.9%-2,790.5%
TTM1,890.9%YOY-1,319.5%+3,210.4%
TTM1,890.9%5Y-651.2%+2,542.1%
5Y-651.2%10Y-602.0%-49.2%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-899.6%5.6%-905.2%
TTM1,890.9%5.9%+1,885.0%
YOY-1,319.5%6.1%-1,325.6%
5Y-651.2%6.2%-657.4%
10Y-602.0%6.1%-608.1%
4.3.1.2. Return on Assets

Shows how efficient AGIOS PHARM (8AP.SG) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • -5.8% Return on Assets means that AGIOS PHARM (8AP.SG) generated €-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AGIOS PHARM (8AP.SG):

  • The MRQ is -5.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 6.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ-5.8%TTM6.3%-12.1%
TTM6.3%YOY-8.5%+14.8%
TTM6.3%5Y-0.3%+6.6%
5Y-0.3%10Y-2.4%+2.1%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.8%1.3%-7.1%
TTM6.3%1.1%+5.2%
YOY-8.5%1.3%-9.8%
5Y-0.3%1.3%-1.6%
10Y-2.4%1.3%-3.7%
4.3.1.3. Return on Equity

Shows how efficient AGIOS PHARM (8AP.SG) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • -6.3% Return on Equity means AGIOS PHARM (8AP.SG) generated €-0.06 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AGIOS PHARM (8AP.SG):

  • The MRQ is -6.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 6.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-6.3%TTM6.6%-12.9%
TTM6.6%YOY-9.7%+16.3%
TTM6.6%5Y-1.9%+8.5%
5Y-1.9%10Y-4.7%+2.8%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.3%3.7%-10.0%
TTM6.6%3.4%+3.2%
YOY-9.7%3.9%-13.6%
5Y-1.9%3.9%-5.8%
10Y-4.7%3.8%-8.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AGIOS PHARM (8AP.SG).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient AGIOS PHARM (8AP.SG) is operating .

  • Measures how much profit AGIOS PHARM (8AP.SG) makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AGIOS PHARM (8AP.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-36.5%+36.5%
5Y-36.5%10Y-90.7%+54.2%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-12.7%
TTM-8.2%-8.2%
YOY-7.8%-7.8%
5Y-36.5%4.4%-40.9%
10Y-90.7%6.8%-97.5%
4.3.2.2. Operating Ratio

Measures how efficient AGIOS PHARM (8AP.SG) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Other industry mean).
  • An Operation Ratio of 12.77 means that the operating costs are €12.77 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of AGIOS PHARM (8AP.SG):

  • The MRQ is 12.770. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.776. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ12.770TTM12.776-0.005
TTM12.776YOY15.786-3.011
TTM12.7765Y15.932-3.156
5Y15.93210Y14.059+1.872
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ12.7701.313+11.457
TTM12.7761.355+11.421
YOY15.7861.375+14.411
5Y15.9321.324+14.608
10Y14.0591.381+12.678
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AGIOS PHARM (8AP.SG).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if AGIOS PHARM (8AP.SG) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Other industry mean).
  • A Current Ratio of 11.90 means the company has €11.90 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of AGIOS PHARM (8AP.SG):

  • The MRQ is 11.898. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.955. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.898TTM10.955+0.943
TTM10.955YOY13.902-2.947
TTM10.9555Y14.867-3.912
5Y14.86710Y13.420+1.447
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ11.8981.426+10.472
TTM10.9551.416+9.539
YOY13.9021.538+12.364
5Y14.8671.562+13.305
10Y13.4201.496+11.924
4.4.3.2. Quick Ratio

Measures if AGIOS PHARM (8AP.SG) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • A Quick Ratio of 10.12 means the company can pay off €10.12 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AGIOS PHARM (8AP.SG):

  • The MRQ is 10.123. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.396. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.123TTM8.396+1.727
TTM8.396YOY11.385-2.989
TTM8.3965Y10.311-1.915
5Y10.31110Y9.410+0.901
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ10.1230.531+9.592
TTM8.3960.553+7.843
YOY11.3850.603+10.782
5Y10.3110.606+9.705
10Y9.4100.609+8.801
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AGIOS PHARM (8AP.SG).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of AGIOS PHARM (8AP.SG) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AGIOS PHARM (8AP.SG) to Other industry mean.
  • A Debt to Asset Ratio of 0.07 means that AGIOS PHARM (8AP.SG) assets are financed with 7.3% credit (debt) and the remaining percentage (100% - 7.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AGIOS PHARM (8AP.SG):

  • The MRQ is 0.073. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.109. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.073TTM0.109-0.035
TTM0.109YOY0.116-0.007
TTM0.1095Y0.166-0.057
5Y0.16610Y0.189-0.023
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0730.520-0.447
TTM0.1090.529-0.420
YOY0.1160.523-0.407
5Y0.1660.555-0.389
10Y0.1890.564-0.375
4.5.4.2. Debt to Equity Ratio

Measures if AGIOS PHARM (8AP.SG) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • A Debt to Equity ratio of 7.9% means that company has €0.08 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AGIOS PHARM (8AP.SG):

  • The MRQ is 0.079. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.123. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.079TTM0.123-0.044
TTM0.123YOY0.132-0.008
TTM0.1235Y0.247-0.123
5Y0.24710Y0.278-0.032
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0791.095-1.016
TTM0.1231.128-1.005
YOY0.1321.155-1.023
5Y0.2471.338-1.091
10Y0.2781.429-1.151
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings AGIOS PHARM (8AP.SG) generates.

  • Above 15 is considered overpriced but always compare AGIOS PHARM (8AP.SG) to the Other industry mean.
  • A PE ratio of -5.08 means the investor is paying €-5.08 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AGIOS PHARM (8AP.SG):

  • The EOD is -4.596. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.078. Based on the earnings, the company is expensive. -2
  • The TTM is -4.003. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.596MRQ-5.078+0.482
MRQ-5.078TTM-4.003-1.075
TTM-4.003YOY-3.875-0.128
TTM-4.0035Y-4.541+0.537
5Y-4.54110Y-4.108-0.433
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD-4.59614.089-18.685
MRQ-5.07813.537-18.615
TTM-4.00312.493-16.496
YOY-3.87511.191-15.066
5Y-4.54112.976-17.517
10Y-4.10813.175-17.283
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AGIOS PHARM (8AP.SG):

  • The EOD is -3.307. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.654. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.909. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.307MRQ-3.654+0.347
MRQ-3.654TTM-5.909+2.255
TTM-5.909YOY-4.415-1.494
TTM-5.9095Y-6.239+0.330
5Y-6.23910Y-5.199-1.040
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD-3.3078.643-11.950
MRQ-3.6548.169-11.823
TTM-5.9097.139-13.048
YOY-4.4155.896-10.311
5Y-6.2393.220-9.459
10Y-5.1993.714-8.913
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of AGIOS PHARM (8AP.SG) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Other industry mean).
  • A PB ratio of 1.27 means the investor is paying €1.27 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of AGIOS PHARM (8AP.SG):

  • The EOD is 1.152. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.272. Based on the equity, the company is underpriced. +1
  • The TTM is 2.198. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.152MRQ1.272-0.121
MRQ1.272TTM2.198-0.926
TTM2.198YOY1.476+0.722
TTM2.1985Y2.394-0.195
5Y2.39410Y2.202+0.192
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD1.1521.532-0.380
MRQ1.2721.404-0.132
TTM2.1981.428+0.770
YOY1.4761.405+0.071
5Y2.3941.718+0.676
10Y2.2021.715+0.487
4.6.2. Total Gains per Share

2.4. Latest News of AGIOS PHARM (8AP.SG)

Does AGIOS PHARM (8AP.SG) still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from AGIOS PHARM (8AP.SG) to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-02-15
16:05
Agios Pharmaceuticals price target lowered to $74 from $75 at ScotiabankRead
2025-02-14
12:33
Agios Pharmaceuticals Full Year 2024 Earnings: Beats ExpectationsRead
2025-02-14
08:09
Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...Read
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,663,199
Total Liabilities122,243
Total Stockholder Equity1,540,956
 As reported
Total Liabilities 122,243
Total Stockholder Equity+ 1,540,956
Total Assets = 1,663,199

Assets

Total Assets1,663,199
Total Current Assets965,600
Long-term Assets697,599
Total Current Assets
Cash And Cash Equivalents 76,247
Short-term Investments 817,463
Net Receivables 4,109
Inventory 27,616
Other Current Assets 40,165
Total Current Assets  (as reported)965,600
Total Current Assets  (calculated)965,600
+/-0
Long-term Assets
Property Plant Equipment 54,554
Long Term Investments 638,321
Long-term Assets Other 4,724
Long-term Assets  (as reported)697,599
Long-term Assets  (calculated)697,599
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities81,156
Long-term Liabilities41,087
Total Stockholder Equity1,540,956
Total Current Liabilities
Accounts payable 16,643
Total Current Liabilities  (as reported)81,156
Total Current Liabilities  (calculated)16,643
+/- 64,513
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt56,988
Long-term Liabilities  (as reported)41,087
Long-term Liabilities  (calculated)56,988
+/- 15,901
Total Stockholder Equity
Total Stockholder Equity (as reported)1,540,956
Total Stockholder Equity (calculated)0
+/- 1,540,956
Other
Capital Stock73
Common Stock Shares Outstanding 57,156
Net Invested Capital 1,540,956
Net Working Capital 884,444
Property Plant and Equipment Gross 111,051



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
822,131
783,870
698,616
890,741
799,738
976,141
908,449
852,952
2,488,434
1,874,603
1,541,498
1,437,736
1,335,859
1,252,467
1,180,320
1,238,718
1,151,298
1,085,153
1,007,258
937,118
849,709
773,063
1,791,794
1,663,199
1,663,1991,791,794773,063849,709937,1181,007,2581,085,1531,151,2981,238,7181,180,3201,252,4671,335,8591,437,7361,541,4981,874,6032,488,434852,952908,449976,141799,738890,741698,616783,870822,131
   > Total Current Assets 
557,095
533,705
490,144
611,704
587,274
846,355
669,086
636,677
2,355,114
1,702,562
1,305,285
1,064,231
975,145
870,007
784,935
832,772
791,656
757,239
704,352
833,835
663,627
632,127
1,074,189
965,600
965,6001,074,189632,127663,627833,835704,352757,239791,656832,772784,935870,007975,1451,064,2311,305,2851,702,5622,355,114636,677669,086846,355587,274611,704490,144533,705557,095
       Cash And Cash Equivalents 
103,443
83,580
81,709
80,931
89,093
295,858
104,855
127,436
1,888,025
969,124
400,224
203,126
80,026
88,543
122,449
139,259
104,139
84,753
64,333
88,205
118,764
84,518
253,730
76,247
76,247253,73084,518118,76488,20564,33384,753104,139139,259122,44988,54380,026203,126400,224969,1241,888,025127,436104,855295,85889,09380,93181,70983,580103,443
       Short-term Investments 
421,114
411,810
370,188
483,946
439,528
494,270
500,684
445,493
447,578
703,864
865,833
816,892
843,503
730,766
605,231
643,860
635,062
617,813
583,155
688,723
479,227
485,374
751,027
817,463
817,463751,027485,374479,227688,723583,155617,813635,062643,860605,231730,766843,503816,892865,833703,864447,578445,493500,684494,270439,528483,946370,188411,810421,114
       Net Receivables 
10,514
14,593
12,413
15,319
19,723
18,037
23,315
25,399
0
0
0
0
540
1,598
1,818
2,206
1,778
2,251
1,176
2,810
3,453
3,762
3,118
4,109
4,1093,1183,7623,4532,8101,1762,2511,7782,2061,8181,598540000025,39923,31518,03719,72315,31912,41314,59310,514
       Inventory 
2,328
4,659
5,849
7,331
9,778
11,231
11,371
14,698
0
0
0
0
2,485
4,060
5,176
8,492
11,374
15,671
17,274
19,076
23,070
23,937
26,429
27,616
27,61626,42923,93723,07019,07617,27415,67111,3748,4925,1764,0602,485000014,69811,37111,2319,7787,3315,8494,6592,328
   > Long-term Assets 
265,036
250,165
208,472
279,037
212,464
129,786
239,363
216,275
133,320
172,041
236,213
373,505
360,714
382,460
395,385
405,946
359,642
327,914
302,906
103,283
186,082
140,936
717,605
697,599
697,599717,605140,936186,082103,283302,906327,914359,642405,946395,385382,460360,714373,505236,213172,041133,320216,275239,363129,786212,464279,037208,472250,165265,036
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
93,130
88,116
83,959
79,500
73,947
69,791
65,725
61,476
57,660
54,554
54,55457,66061,47665,72569,79173,94779,50083,95988,11693,13000000000000000
       Long Term Investments 
183,234
128,649
88,579
152,929
84,503
4,285
116,889
97,608
21,598
61,313
130,139
266,375
255,836
280,845
298,352
313,874
271,727
244,357
224,902
29,435
116,301
75,404
655,889
638,321
638,321655,88975,404116,30129,435224,902244,357271,727313,874298,352280,845255,836266,375130,13961,31321,59897,608116,8894,28584,503152,92988,579128,649183,234
       Long-term Assets Other 
60
250,165
208,472
279,037
1,800
1,575
1,350
1,125
0
2,900
2,900
2,900
2,900
3,955
3,903
3,956
3,956
4,057
4,057
4,057
4,056
4,056
4,056
4,724
4,7244,0564,0564,0564,0574,0574,0573,9563,9563,9033,9552,9002,9002,9002,90001,1251,3501,5751,800279,037208,472250,16560
> Total Liabilities 
201,874
251,193
250,325
250,213
174,439
417,676
427,997
453,452
191,804
152,787
146,736
145,761
128,406
128,397
130,150
137,904
114,772
120,917
120,415
126,099
105,787
112,553
165,122
122,243
122,243165,122112,553105,787126,099120,415120,917114,772137,904130,150128,397128,406145,761146,736152,787191,804453,452427,997417,676174,439250,213250,325251,193201,874
   > Total Current Liabilities 
80,907
89,504
92,432
92,886
69,858
64,353
69,771
94,394
96,504
60,649
57,896
59,826
45,792
48,396
53,596
62,629
45,113
55,141
58,425
67,955
51,691
62,637
119,451
81,156
81,156119,45162,63751,69167,95558,42555,14145,11362,62953,59648,39645,79259,82657,89660,64996,50494,39469,77164,35369,85892,88692,43289,50480,907
       Accounts payable 
12,413
15,435
21,511
21,896
18,707
15,461
12,853
26,844
51,224
7,654
10,308
16,700
11,551
7,790
10,415
18,616
8,662
11,626
13,271
9,780
11,155
10,035
17,143
16,643
16,64317,14310,03511,1559,78013,27111,6268,66218,61610,4157,79011,55116,70010,3087,65451,22426,84412,85315,46118,70721,89621,51115,43512,413
   > Long-term Liabilities 
120,967
161,689
157,893
157,327
104,581
353,323
358,226
359,058
95,300
92,138
88,840
85,935
82,614
80,001
76,554
75,275
69,659
65,776
61,990
58,144
54,096
49,916
45,671
41,087
41,08745,67149,91654,09658,14461,99065,77669,65975,27576,55480,00182,61485,93588,84092,13895,300359,058358,226353,323104,581157,327157,893161,689120,967
       Capital Lease Obligations Min Short Term Debt
75,134
116,470
115,394
113,662
111,353
109,346
107,299
105,199
103,609
101,909
99,135
97,094
94,608
91,169
88,924
85,659
82,338
78,946
75,498
71,996
68,347
64,620
60,834
56,988
56,98860,83464,62068,34771,99675,49878,94682,33885,65988,92491,16994,60897,09499,135101,909103,609105,199107,299109,346111,353113,662115,394116,47075,134
> Total Stockholder Equity
620,257
532,677
448,291
640,528
625,299
558,465
480,452
399,500
2,296,630
1,721,816
1,394,762
1,291,975
1,207,453
1,124,070
1,050,170
1,100,814
1,036,526
964,236
886,843
811,019
743,922
660,510
1,626,672
1,540,956
1,540,9561,626,672660,510743,922811,019886,843964,2361,036,5261,100,8141,050,1701,124,0701,207,4531,291,9751,394,7621,721,8162,296,630399,500480,452558,465625,299640,528448,291532,677620,257
   Common Stock000000000000000000000000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue36,498
Cost of Revenue-4,165
Gross Profit32,33332,333
 
Operating Income (+$)
Gross Profit32,333
Operating Expense-462,235
Operating Income-425,737-429,902
 
Operating Expense (+$)
Research Development301,286
Selling General Administrative156,784
Selling And Marketing Expenses-
Operating Expense462,235458,070
 
Net Interest Income (+$)
Interest Income48,083
Interest Expense--
Other Finance Cost-0
Net Interest Income48,083
 
Pretax Income (+$)
Operating Income-425,737
Net Interest Income48,083
Other Non-Operating Income Expenses-
Income Before Tax (EBT)717,969-1,521,360
EBIT - interestExpense = 0
673,725
673,725
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-717,969
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax717,969
Tax Provision-44,244
Net Income From Continuing Ops673,725673,725
Net Income673,725
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net1,095,623-48,083
 

Technical Analysis of AGIOS PHARM (8AP.SG)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AGIOS PHARM (8AP.SG). The general trend of AGIOS PHARM (8AP.SG) is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AGIOS PHARM (8AP.SG)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. AGIOS PHARM (8AP.SG) Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AGIOS PHARM (8AP.SG).

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 28.80 < 30.20 < 30.80.

The bearish price targets are: 28.60 > 25.40 > 25.40.

Tweet this
AGIOS PHARM (8AP.SG) Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AGIOS PHARM (8AP.SG). The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AGIOS PHARM (8AP.SG) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AGIOS PHARM (8AP.SG). The current macd is -1.0613048.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the AGIOS PHARM (8AP.SG) price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for AGIOS PHARM (8AP.SG). This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the AGIOS PHARM (8AP.SG) price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
AGIOS PHARM (8AP.SG) Daily Moving Average Convergence/Divergence (MACD) ChartAGIOS PHARM (8AP.SG) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AGIOS PHARM (8AP.SG). The current adx is 25.59.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell AGIOS PHARM (8AP.SG) shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
AGIOS PHARM (8AP.SG) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AGIOS PHARM (8AP.SG). The current sar is 33.49.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
AGIOS PHARM (8AP.SG) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AGIOS PHARM (8AP.SG). The current rsi is 30.98. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
AGIOS PHARM (8AP.SG) Daily Relative Strength Index (RSI) ChartAGIOS PHARM (8AP.SG) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AGIOS PHARM (8AP.SG). The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the AGIOS PHARM (8AP.SG) price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
AGIOS PHARM (8AP.SG) Daily Stochastic Oscillator ChartAGIOS PHARM (8AP.SG) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AGIOS PHARM (8AP.SG). The current cci is -143.3673025.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
AGIOS PHARM (8AP.SG) Daily Commodity Channel Index (CCI) ChartAGIOS PHARM (8AP.SG) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AGIOS PHARM (8AP.SG). The current cmo is -51.51254402.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
AGIOS PHARM (8AP.SG) Daily Chande Momentum Oscillator (CMO) ChartAGIOS PHARM (8AP.SG) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AGIOS PHARM (8AP.SG). The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
AGIOS PHARM (8AP.SG) Daily Williams %R ChartAGIOS PHARM (8AP.SG) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AGIOS PHARM (8AP.SG).

AGIOS PHARM (8AP.SG) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AGIOS PHARM (8AP.SG). The current atr is 0.797984.

AGIOS PHARM (8AP.SG) Daily Average True Range (ATR) ChartAGIOS PHARM (8AP.SG) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AGIOS PHARM (8AP.SG). The current obv is -422.

AGIOS PHARM (8AP.SG) Daily On-Balance Volume (OBV) ChartAGIOS PHARM (8AP.SG) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AGIOS PHARM (8AP.SG). The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
AGIOS PHARM (8AP.SG) Daily Money Flow Index (MFI) ChartAGIOS PHARM (8AP.SG) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AGIOS PHARM (8AP.SG).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

AGIOS PHARM (8AP.SG) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AGIOS PHARM (8AP.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.985
Ma 20Greater thanMa 5031.400
Ma 50Greater thanMa 10031.924
Ma 100Greater thanMa 20038.774
OpenGreater thanClose28.600
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of AGIOS PHARM (8AP.SG) with someone you think should read this too:
  • Are you bullish or bearish on AGIOS PHARM (8AP.SG)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about AGIOS PHARM (8AP.SG)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AGIOS PHARM (8AP.SG)

I send you an email if I find something interesting about AGIOS PHARM (8AP.SG).


Comments

How you think about this?

Leave a comment

Stay informed about AGIOS PHARM (8AP.SG).

Receive notifications about AGIOS PHARM (8AP.SG) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.